Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies

25 Nov 2010

Abstract excerpt

To broaden the applicability of adoptive T-cell therapy for the treatment of hematologic malignancies, we aim to start a clinical trial using HA-1-TCR transferred virus-specific T cells. TCRs directed against the minor histocompatibility antigen (MiHA) HA-1 are good candidates for TCR gene transfer to treat hematologic malignancies because of the hematopoiesis-restricted expression and favorable frequency of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Cytomegalovirus and herpesvirus research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21109688
DOI: 10.3324/haematol.2010.025916

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignanciesPMID 21109688Read ↗

Therapeutic Applications of Engineered Chimeric Antigen Receptors-T cell for Cancer TherapySemantic proximity Read ↗

Challenges in T cell receptor gene therapySemantic proximity Read ↗

Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDSSemantic proximity Read ↗

T Cell Receptor Gene Therapy for CancerSemantic proximity Read ↗

HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantationSemantic proximity Read ↗

Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCRSemantic proximity Read ↗

Trends in cell medicine: from autologous cells to allogeneic universal-use cells for adoptive T-cell therapiesSemantic proximity Read ↗

IL-7 receptor expression identifies suicide gene–modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectorsSemantic proximity Read ↗

Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical applicationSemantic proximity Read ↗

Monoclonal T-Cell Receptors: New Reagents for Cancer TherapySemantic proximity Read ↗

Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptorSemantic proximity Read ↗

Targeting self-antigens through allogeneic TCR gene transferSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.